EOM Pharmaceuticals

EOM Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel immunomodulatory therapies for inflammatory and immune-mediated diseases. The company's lead asset, EOM613, is a dual-action peptide-based formulation designed to suppress pro-inflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) while simultaneously inducing anti-inflammatory cytokines like interleukin 10 (IL-10). This unique mechanism of action is being explored for the treatment of cancer cachexia, rheumatoid arthritis, and severe COVID-19. In 2022, the company entered into a significant licensing agreement with BiondVax Pharmaceuticals for the further development of EOM613. EOM Pharmaceuticals continues to oversee its strategic portfolio to address high unmet medical needs in oncology and immunology.